Autopsy report · NCT04708834

Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.

“Sponsor Decision”

The sponsor’s own words in the registry.

Life of this trial

Registered 3 months before it started.
Ran for about 4 years 10 months before it stopped.
772 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: Biohaven Pharmaceuticals, Inc.
Sponsor type: Industry
Conditions: Obsessive Compulsive Disorder
Interventions: Troriluzole (BHV-4157)
Participants: 772
Sites: 175
Countries: Canada, Italy, Netherlands, Spain, United Kingdom, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.